Foetal Outcomes Sample Clauses

Foetal Outcomes. The overall foetal mortality rate was 7% (4/60). This comprised of 4 deaths; 2 deaths occurred in foetuses from patients with HELLP syndrome, whereas 2 occurred in patients with AFLP. Three of the four foetal deaths occurred in women with twin pregnancies. The first foetal death was in a 35 year old woman who was pregnant with twins, and presented at 30 weeks gestation with HELLP syndrome complicated by a sub-capsular haematoma. An emergency caesarean section was preformed but the second twin was still born. The subsequent two foetal deaths occurred in a 30 year old woman who presented with abdominal pain at 34 weeks gestation, was diagnosed with AFLP and went into spontaneous labour 36 hours after presentation. Unfortunately both her twins were still born. She subsequently developed grade IV encephalopathy, required intubation for airway protection, but recovered with supportive medical care. The final foetal death occurred in a 28 year old women who presented with nausea, vomiting and abdominal pain at 31 weeks gestation. She was diagnosed with HELLP syndrome, which was complicated by ischaemic hepatitis secondary to placental abruption. The baby was delivered vaginally, but was still born. The women developed ascites and renal failure but recovered with supportive medical care. Interestingly foetal death was not associated with the severity of the maternal liver disease, as guided by maternal platelet count, INR, bilirubin, AST, creatinine or the presence of encephalopathy. (Table 4.5.3) This is likely due to the rapid delivery of the fetus. (90% within 24 hours) Table 4.5.3: Severity of maternal liver disease at presentation and impact on foetal survival Foetal Death (n=4) Foetal Survival (n=56) Median age at presentation 30 (28-35) 30 (21-40) Week of gestation 31 (30-34) 35 (27-40) Number encephalopathic 1 6 99 (58-116) 55 (15-225) Platelet count (150-450 cells/µL) Creatinine (45-120 mg/dL) 247 (67-262) 152 (52-396) AST (10-50 IU/L) 975 (78-5041) 307 (16-775) Bilirubin (3-20 µmol/L) 53 (30-87) 63 (9-388) Lactate (<2 mg/dl) 2.0 (0.7-2.9) 2.0 (0.8-18.0) INR (0.9-1.2) 1.06 (1.03 – 1.58) 1.40 (0.84-4.3) Thirteen neonates required admission to the special care baby unit for supportive care and all were subsequently discharged, with no ongoing medical sequelae. Admission to the SCBU was associated with earlier maternal gestation (34 (27-36) vs. 36 (35-42)).
View Source

Related to Foetal Outcomes

  • Outcomes Secondary: Career pathway students will: have career goals designated on SEOP, earn concurrent college credit while in high school, achieve a state competency certificate and while completing high school graduation requirements.

  • Geometric visibility The visibility of the illuminating surface, including its visibility in areas which do not appear to be illuminated in the direction of observation considered, shall be ensured within a divergent space defined by generating lines based on the perimeter of the illuminating surface and forming an angle of not less than 5° with the axis of reference of the headlamp.

  • Intrusion Detection All systems involved in accessing, holding, transporting, and protecting DHCS PHI or PI that are accessible via the Internet must be protected by a comprehensive intrusion detection and prevention solution.

  • Study Population ‌ Infants who underwent creation of an enterostomy receiving postoperative care and awaiting enterostomy closure: to be assessed for eligibility: n = 201 to be assigned to the study: n = 106 to be analysed: n = 106 Duration of intervention per patient of the intervention group: 6 weeks between enterostomy creation and enterostomy closure Follow-up per patient: 3 months, 6 months and 12 months post enterostomy closure, following enterostomy closure (12-month follow-up only applicable for patients that are recruited early enough to complete this follow-up within the 48 month of overall study duration).

  • Therapies Acupuncture and acupuncturist services, including x-ray and laboratory services. • Biofeedback, biofeedback training, and biofeedback by any other modality for any condition. • Recreational therapy services and programs, including wilderness programs. • Services provided in any covered program that are recreational therapy services, including wilderness programs, educational services, complimentary services, non- medical self-care, self-help programs, or non-clinical services. Examples include, but are not limited to, Tai Chi, yoga, personal training, meditation. • Computer/internet/social media based services and/or programs. • Recreational therapy. • Aqua therapy unless provided by a physical therapist. • Maintenance therapy services unless it is a habilitative service that helps a person keep, learn or improve skills and functioning for daily living. • Aromatherapy. • Hippotherapy. • Massage therapy rendered by a massage therapist. • Therapies, procedures, and services for the purpose of relieving stress. • Physical, occupational, speech, or respiratory therapy provided in your home, unless through a home care program. • Pelvic floor electrical and magnetic stimulation, and pelvic floor exercises. • Educational classes and services for speech impairments that are self-correcting. • Speech therapy services related to food aversion or texture disorders. • Exercise therapy. • Naturopathic, homeopathic, and Christian Science services, regardless of who orders or provides the services. • Eye exercises and visual training services. • Lenses and/or frames and contact lenses for members aged nineteen (19) and older. • Vision hardware purchased from a non-network provider. • Non-collection vision hardware. • Lenses and/or frames and contact lenses unless specifically listed as a covered healthcare service.